Table 1. Patient Characteristics Patient... | American Society of Hematology

Table 1.

Patient Characteristics

Patient No.	Age (yr)	Date of Diagnosis	Prior Chemotherapy	Date of Recurrence	Sites of Disease	Response	Comments
1	36	4/10/95	CAF	2/14/96	Bone	EI	PD 10/27/97
2	37	10/2/91	CAF	4/24/96	Lung, bone	EI	PD 3/10/98
3	48	8/5/91	CAF	5/14/96	Lung, bone	EI	Alive w/o progression
4	67	5/18/94	CMF	8/8/96	Chest wall, lung	PR	PD 11/13/97
5	39	2/9/96	NONE	—	Chest wall	EI	Alive w/o progression
6	49	1/21/88	CMF, TAM	8/28/96	Chest wall, nodes	PR	Alive w/o progression

Patient No.	Age (yr)	Date of Diagnosis	Prior Chemotherapy	Date of Recurrence	Sites of Disease	Response	Comments
1	36	4/10/95	CAF	2/14/96	Bone	EI	PD 10/27/97
2	37	10/2/91	CAF	4/24/96	Lung, bone	EI	PD 3/10/98
3	48	8/5/91	CAF	5/14/96	Lung, bone	EI	Alive w/o progression
4	67	5/18/94	CMF	8/8/96	Chest wall, lung	PR	PD 11/13/97
5	39	2/9/96	NONE	—	Chest wall	EI	Alive w/o progression
6	49	1/21/88	CMF, TAM	8/28/96	Chest wall, nodes	PR	Alive w/o progression

Abbreviations: CAF, cyclophosphamide, doxorubicin, fluorouracil; CMF, cyclophosphamide, methotrexate, fluorouracil; TAM, tamoxifen; EI, evaluable improved; PR, partial response; PD, progressive disease.